Ann: Webinar Presentation - Phase IIb study of avicursen, page-5

First 5 Last

Share
Profile

Follow
bajachris88

394 Posts.

207

06/02/25

10:09

Post #: 77729341
Share

Originally posted by RYNZN: ↑

First 15mins and we are rehashing a disease we have no interest in anymore. Anyway; my notes fwiw

- Subjective on behalf of the patient. Nevertheless best thing we have
- placebo shows same result as drug
- consistency of results show nothing
- no discontinuations due to adverse events
- adverse events inline with if the drug worked
- pk and pd effects; cd49d 50mg showed a reduction of 17%, 25mg 0%, placebo 18%. Decrease in Serum Creatine Kinase 50mg -18%.
- moving off placebo did nothing

Patients knew they were on active drug for ph2a = Hopium.
Dropping of cd49d is not enough to have a substantial outcome

MRI - didn't talk about the Ph2a result, just how it was difficult to manage in ph2b multisite. My question not answered, why MRI showed proof beyond placebo in ph2a.
Post trial access; some patients are doing well and the hope that the drug is the cause... there's so little else to hope on.
Longer study wouldn't have showed a difference. Higher drug dose may show signals, but safety issues come into play
Shelf life; doesn't require controlled storage conditions, not fragile (seemingly!?), checked some vials of drugs for damage, concentration looked exactly as it should.
Lots of audits along the way eg. no sabotage possibilities
First injection at clinical site, taught caregivers how to give injection at home.
Dr Voit's response; shared disappointment
Abbreviated end of study report to close study
ATL1102 is clinically dead.

Expand

Thanks for taking the time to surmise the webinar for us.

Did they allude to the 'now what?!' by any chance?

Or any plans from here?

PER Price at posting: 0.8¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

HotCopper Highlights, Week 24: Israel boosts Energy; Meeka eyes production & Mag7 back

ASX Market Open: Growing war fears to get Week 25 off to poor start | June 16, 2025

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

AVM

'Sure to be busy': Advance's Yuquivo drilling gets off to top start with first-hole hits

Week 24 Wrap: WW3 looms (again); US econ data tepid & silver surfing

First 5 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.0¢		Change 0.000(0.00%)		Mkt cap ! $10.87M

Open	High	Low	Value	Volume
1.0¢	1.0¢	1.0¢	$71.80K	7.180M

Buyers (Bids)

No.	Vol.	Price($)
1	4649246	1.0¢

Sellers (Offers)

Price($)	Vol.	No.
1.1¢	2600000	2

View Market Depth

No.	Vol.	Price($)
1	4649246	0.010
6	5659202	0.009
4	1260267	0.008
5	2282854	0.007
2	3200000	0.005

Price($)	Vol.	No.
0.011	2600000	2
0.012	1439598	4
0.013	1515000	3
0.014	2295834	4
0.015	1500000	1

Last trade - 15.21pm 13/06/2025 (20 minute delay)

PER (ASX) Chart

Ann: Webinar Presentation - Phase IIb study of avicursen, page-5

HotCopper Highlights, Week 24: Israel boosts Energy; Meeka eyes production & Mag7 back

ASX Market Open: Growing war fears to get Week 25 off to poor start | June 16, 2025

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

'Sure to be busy': Advance's Yuquivo drilling gets off to top start with first-hole hits

Week 24 Wrap: WW3 looms (again); US econ data tepid & silver surfing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Webinar Presentation - Phase IIb study of avicursen, page-5

Top Stories

HotCopper Highlights, Week 24: Israel boosts Energy; Meeka eyes production & Mag7 back

ASX Market Open: Growing war fears to get Week 25 off to poor start | June 16, 2025

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

'Sure to be busy': Advance's Yuquivo drilling gets off to top start with first-hole hits

Week 24 Wrap: WW3 looms (again); US econ data tepid & silver surfing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News